|
 |
|
|
Board of Directors
Lisa Suennen Ms. Suennen is Chairman of the AngioScore Board and is a co-founder and Managing Member of Psilos Group, a healthcare-focused venture capital and growth equity firm with over $580 million under management. Ms. Suennen has headed Psilos' West Coast office since the firm's founding in 1998 and focuses on the medical device, healthcare information technology and healthcare services sectors. She serves as a Director on the Board of several Psilos portfolio companies, including PatientSafe Solutions, OmniGuide and VeraLight, Inc. Prior to Psilos, Ms. Suennen spent 9 years at Merit Behavioral Care where she held various senior executive roles from its start-up days until its sale for $800 million to Magellan in 1998. She previously worked in the high technology field at Ingres, X/Open and Regis McKenna, Inc. Ms. Suennen holds graduate and undergraduate degrees from the University of California, Berkeley where she now sits on the National Advisory Board of the Institute for Governmental Studies and is a visiting lecturer at the U.C. Berkeley Haas School of Business.
J. Neal Armstrong, CPA Mr. Armstrong joined Aspect Medical Systems, Inc. in 1996 and served as Vice President, Chief Financial Officer, Secretary and Treasurer until January 2005 when he retired as an officer of Aspect. Mr. Armstrong currently serves on the board of directors for deCode Genetics, Salient Surgical, TransMedics and VapoTherm. From 1990 to 1996, Mr. Armstrong served as Vice President of Finance, Chief Financial Officer and as a director of Haemonetics, Inc., a manufacturer of blood processing systems. From 1985 to 1990, he was the Vice President of Finance and Administration, Treasurer and Chief Financial Officer at BTU International, Inc., a manufacturer of thermal processing systems. Prior to 1985, he served for 14 years in various senior operating and financial positions at Texas Instruments, Inc., an electronics company. Mr. Armstrong holds a Bachelor degree in accounting from the University of Texas and is a Certified Public Accountant.
Robert (Bob) A. Elliott Bob Elliott is currently Chairman of Elliott Investment Company, Newport Beach, California. Elliott Investment Company specializes in investments in selected device start-up ventures, as well as providing consulting services to such start-ups. Prior to founding his own company, Bob was the Chairman and CEO of VLI Corporation, Irvine, California. VLI was the manufacturer and worldwide marketer of the Today Vaginal Contraceptive Sponge and other personal care products. VLI was sold to American Home Products in 1987. Prior to joining VLI, Bob was Vice President of Howmedica, Incorporated, a wholly owned subsidiary of Pfizer. Before joining Howmedica, Bob was President and CEO of Shiley, Inc. a major worldwide supplier of cardiovascular and respiratory care products. Shiley was sold to Pfizer in 1980. Bob has been a Director of Intermark, Inc., Triton, Inc., RemedyTemp, Inc. and the Rusty Pelican Restaurants. He has also invested in and/or was a Director in numerous private medical device companies including: Denar, Steri-Oss Dental, CareCredit, Advanced Surgical Intervention, Woodruff Laboratories and Polymer Technology Group. Bob is also a member of the Board of Trustees of Chapman University and a member of the University of Southern California Athletic Department Board of Counselors. Bob holds a B.S. Degree in Marketing from California State University and an MBA from the University of Southern California.
Scott Halsted Mr. Halsted is currently a Managing Director for Saints Capital. Mr. Halsted has over 20 years of investment experience in the healthcare field. Prior to joining Saints, from 1987-2007 he was a managing member of Morgan Stanley Ventures where he was responsible for making growth equity investments in emerging health care companies. As co-head of the healthcare practice, Mr. Halsted was responsible for more than $300 million of investments in over 40 companies. Mr. Halsted has served on seventeen Boards of Directors including both private and public companies. Currently, Mr. Halsted is a board member at Endoscopic Technologies, DiscoveRx and Innfocus and a board observer at Incline Therapeutics. Illustrative investments include Arcadian Health Management, Benefitmall (acquired by Allied Capital), Cytyc (acquired by Hologic), Emphasys, Idec Pharmaceutical (merged with Biogen), Intuitive Surgical (ISRG), Microgenics (acquired by Sybron), Milestone Healthcare (acquired by HCR), Neurex (acquired by Elan), R2 Technology (acquired by Hologic), and Reva Medical. Prior to his investment career, Mr. Halsted worked in the medical technology field in the areas of product design and business development for Intermedics Orthopedics and Hexcel Medical. Mr. Halsted holds an AB degree from Dartmouth College as well as a BE degree in biomechanical engineering from the Thayer School of Engineering at Dartmouth College. He also holds an MM degree from Northwestern University.
Dalia Megiddo, MD, MBA Dr Megiddo has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment community both in Israel and internationally. She was the managing partner of 7 Health ventures, one of the leading Israeli healthcare funds. Dr. Megiddo is also a managing partner in InnoMed Ventures, another leading Israeli healthcare venture fund. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging (NASDAQ-GIVN) and Elron (NASDAQ- ELRN). She is also involved in founding several successful companies such as Medingo, Chiasma and Alcobra. Dr. Megiddo founded and sold two successful businesses in the medical field: The Journal Club - Israel's leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians. Dr Megiddo holds an MBA from Kellogg- Recanti School of Business. She completed her medical studies at the Hebrew University's Hadassah Medical School.
Glenn W. Novotny Glenn was most recently the CEO of Central Garden & Pet, (NASDAQ-CENT), with sales of $1.7 billion. He worked at Central for 17 years as President and Chief Operating Officer from 1990 to 2003 and CEO from 2003 through 2007. Glenn was instrumental in taking the company public in 1993 and growing it from annual sales of $200 million to $1.7 billion through organic growth and over 40 acquisitions to consolidate the pet and garden supplies industries in the US and Europe. He also worked at Weyerhaeuser Corporation from 1970 to 1990 in a variety of operating, strategic planning, sales, and executive management roles. He served as CEO of Weyerhaeuser Garden Supply from 1988 to1990. Glenn has served on both public and private boards and also had significant entrepreneurial experiences in his career. Glenn has represented THP on the boards of Freedom Innovations, Confirma and NEXUS Biosystems (acquired by Brooks Automation). Glenn received a BA from Chadron State College in Nebraska and graduated from the Harvard Business School Executive Management Program.
Thomas A. Raffin, M.D. Thomas A. Raffin, M.D. Co-Founder and General Partner in Telegraph Hill Partners, a life sciences and health care private equity firm in San Francisco www.thpartners.net Tom has spent 27 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. Over the past decade he has worked extensively in the healthcare and medical device sectors and is co-founder of Rigel Pharmaceuticals. Currently, Tom is a director of AngioScore, Confirma, Freedom Innovations, LDR, NewLink Genetics, PneumRx and is an advisor to numerous other companies. He is an active investigator, and has written over 200 publications. Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and medical residency at Harvard.
Benjamin S. Schapiro In 1966, Ben began his career in investment banking at Robert Garrett & Sons, which merged into Alex. Brown & Sons in 1974. Throughout his 32-year tenure, his efforts encompassed institutional, international and private client accounts, real estate finance, corporate finance, merger and acquisition transactions as well as public and private investing in emerging growth companies. In 1998, he left Alex. Brown to organize QuestMark Partners with the original investment criteria and objectives that exist today. He has served as chairman, vice chairman and trustee or board member of a number of endowment funds, charitable organizations and professionally managed portfolios. Ben graduated from Randolph-Macon College in 1964 with a degree in Economics. Ben currently is or has been a member or active observer on the boards of Align Technology (ALGN), AngioScore, Aspect Medical Systems (ASPM), eHealth (EHTH), GeneOhm Sciences (BDX), GenVault, Hospital Partners of America, Nimblefish, SeniorHealth, TissueLink Medical, Vapotherm and Xirrus.
Thomas R. Trotter Thomas R. Trotter joined AngioScore in August 2005 as President and CEO. Mr. Trotter brings to AngioScore more than 30 years experience in the medical device business. Most recently, he served as President and CEO of OrthoLogic, Inc., a public orthopedics company. Prior to OrthoLogic, Mr. Trotter worked for Mallinckrodt, Inc. as President of the Critical Care Division, which included 2500 employees and over $400 million in annual revenues. He joined Mallinckrodt via the acquisition of Diamond Sensor Systems, a venture-backed medical device company in the blood chemistry analysis business, where he served as President and CEO. Previously, Mr. Trotter worked for Shiley, Inc., then a division of Pfizer, where he managed the worldwide cardiopulmonary business. Mr. Trotter holds an MBA from Pepperdine University and a B.S. in business administration from the University of Maryland. He is also a senior fellow of the Holmes Society at Harvard University.
|
© 2004 - 2012 AngioScore, Inc. All Rights Reserved. Terms of Use Privacy Statement |
